EZH2 and non-small cell lung carcinoma: Notably, NSCLC patients whose tumors exhibited higher EZH2 expression experienced notably reduced overall survival rates, along with diminished disease-specific and disease-free survival rates, as compared to patients with lower EZH2 expression (P = 0.005, P = 0.001, and P = 0.003, respectively) (76).